|Classification and external resources|
|ICD-10||Q87.1 (ILDS Q87.114)|
Silver–Russell dwarfism, also called Silver–Russell syndrome (SRS) or Russell–Silver syndrome (RSS) is a growth disorder occurring in approximately 1/50,000 to 1/100,000 births. In the United States it is usually referred to as Russell–Silver syndrome, and Silver–Russell syndrome elsewhere. It is one of 200 types of dwarfism and one of five types of primordial dwarfism and is one of the few forms that is considered treatable in some cases.
There is no statistical significance of the syndrome occurring in males or females.
Its exact cause is unknown, but present research points toward a genetic component, possibly following maternal genes.
It involves hypomethylation of H19 and IGF2. In 10% of the cases the syndrome is associated with maternal uniparental disomy (UPD) on chromosome 7. This is an imprinting error where the person receives two copies of chromosome 7 from the mother (maternally inherited) rather than one from each parent.
Like other imprinting disorders (e.g. Prader–Willi syndrome, Angelman syndrome, and Beckwith–Wiedemann syndrome), Silver–Russell syndrome may be associated with the use of assisted reproductive technologies such as in vitro fertilization.
Although confirmation of a specific genetic marker is in a significant number of individuals, there are no tests to clearly determine if this is what a person has. As a 'syndrome' a diagnosis is typically given for children upon confirmation of the presence of several 'symptoms' listed below.  Symptoms are Intrauterine Growth Restriction (IUGR) combined with some of the following:
- Often small for gestational age (SGA) at birth (birth weight less than 2.8 kg)
- Feeding problems: the baby is uninterested in feeding and takes only small amounts with difficulty
- Excessive sweating as a baby, especially at night, and a greyness or pallor of the skin. This may be a symptom of hypoglycemia
- Triangular shaped face with a small jaw and a pointed chin that tends to lessen slightly with age. The mouth tends to curve down
- A blue tinge to the whites of the eyes in younger children
- Head circumference may be of normal size and disproportionate to a small body size
- Wide and late-closing fontanelle
- Body asymmetry: one side of the body grows more slowly than the other
- Continued poor growth with no "catch up" into the normal centile lines on growth chart
- Precocious puberty (occasionally)
- Low muscle tone
- Gastroesophageal reflux disease
- A striking lack of subcutaneous fat
- Late closing of the opening between the heart hemispheres
- Constipation (sometimes severe)
In a very recent research, Dr. Mustafa Ghanim and colleagues suggested that congenital heart defects are part of this syndrome and according to a large cohort of patients (145), these defects were found in about 5.5% of patients (much more than the prevalence of these defects in the general population, which is about 1%). This new research points to the relation between congenital heart defects and epigenetic anomalies.
The caloric intake of children with RSS must be carefully controlled in order to provide the best opportunity for growth. If the child is unable to tolerate oral feeding, then enteral feeding may be used, such as the percutaneous endoscopic gastrostomy.
In children with limb-length differences or scoliosis, physiotherapy can alleviate the problems caused by these symptoms. In more severe cases, surgery to lengthen limbs may be required. To prevent aggravating posture difficulties children with leg length differences may require a raise in their shoe.
Growth hormone therapy is often prescribed as part of the treatment of RSS. The hormones are given by injection typically daily from the age of 2 years old through teenage years. It may be effective even when the patient does not have a growth hormone deficiency. Growth hormone therapy has been shown to increase the rate of growth in patients and consequently prompts 'catch up' growth. This may enable the child to begin their education at a normal height, improving their self-esteem and interaction with other children. The effect of growth hormone therapy on mature and final height is as yet uncertain. There are some theories suggesting that the therapy also assists with muscular development and managing hypoglycemia.
- Bartholdi D, Krajewska-Walasek M, Ounap K, et al. (2009 (March)). "Epigenetic mutations of the imprinted IGF2-H19 domain in Silver-Russell syndrome (SRS): results from a large cohort of patients with SRS and SRS-like phenotypes". J. Med. Genet. 46 (3): 192–7. doi:10.1136/jmg.2008.061820. PMID 19066168.
- "Silver-Russell Syndrome; SRS". OMIM.
- Butler, Merlin G. (2009 (October)). "Genomic imprinting disorders in humans: a mini-review". Journal of Assisted Reproductive Genetics 26 (9-10): 477–486. doi:10.1007/s10815-009-9353-3. PMC 2788689. PMID 19844787. Retrieved 2012-05-30.
- "Russell-Silver Syndrome". patient.co.uk.
- Rakover Y, Dietsch S, Ambler GR, Chock C, Thomsett M, Cowell CT (1996). "Growth hormone therapy in Silver Russell syndrome: 5 years experience of the Australian and New Zealand Growth database (OZGROW)". Eur. J. Pediatr. 155 (10): 851–7. doi:10.1007/BF02282833. PMID 8891553.
- Child Growth Foundation Russell Silver Syndrome
- synd/2892 at Who Named It?
- Russell A (1954). "A syndrome of intra-uterine dwarfism recognizable at birth with cranio-facial dysostosis, disproportionately short arms, and other anomalies (5 examples)". Proc. R. Soc. Med. 47 (12): 1040–4. PMC 1919148. PMID 13237189.
- Silver HK, Kiyasu W, George J, Deamer WC (1953). "Syndrome of congenital hemihypertrophy, shortness of stature, and elevated urinary gonadotropins". Pediatrics 12 (4): 368–76. PMID 13099907.
- Russell-Silver Support.Org
- GeneReviews/NCBI/NIH/UW entry on Russell-Silver Syndrome
- Russell-Silver Syndrome Support - www.rss-support.nl
- http://www.facebook.com/groups/rss.people/#!/groups/rss.people/ (TARSS, Group for teens and adults with Russell Silver Syndrome)
- "Russell Silver Syndrome (RSS)". Child Growth Foundation.
- The MAGIC Foundation, RSS Divison